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Inflammatory aortic aneurysm is associated with
increased incidence of autoimmune disease
E. S. Haug, MD,a J. F. Skomsvoll, MD, PhD,b G. Jacobsen, MD, PhD,c T. B. Halvorsen, MD, PhD,d
O. D. Sæther, MD, PhD,a and H. O. Myhre, MD, PhD,a Trondheim, Norway
Objective: It has been suggested that certain genetic risk factors indicative of an autoimmune mechanism can be identified
in patients with inflammatory aortic aneurysm (IAA). We therefore investigated whether there was a higher incidence of
autoimmune diseases in patients with IAA. Further, we explored risk factors, need for in-hospital resources, and early
results of treatment, in a case-control study in a university hospital setting.
Material and methods: From 1983 to 1994, 520 patients were operated because of abdominal aortic aneurysm (AAA).
Thirty-one patients had IAA. Control subjects were matched for aneurysm rupture, emergency or elective hospital
admission, and date of operation. Two noninflammatory AAA were included for every IAA.
Results: Of the 31 patients with IAA, 6 patients (19%) had autoimmune disease, compared with none of the control
subjects (P  .0017). Two patients had rheumatoid arthritis, 2 patients had systemic lupus erythematosus, 1 had giant
cell arteritis, and 1 patient had an undifferentiated seronegative polyarthritis diagnosed as rheumatoid arthritis. Nineteen
patients (61%) with IAA had involvement of the duodenum, and 8 patients (26%) had hydronephrosis with ureteral
involvement. Operating time was longer in the IAA group, which also had a higher need for blood transfusion. Hospital
stay, intensive care unit stay, and 30-day mortality were similar in the two groups.
Conclusion: Except for longer operating time and more need for blood transfusions in the IAA group, use of hospital
resources was similar after operations to treat IAA or noninflammatory AAA. The study findings indicate an association
between IAA and autoimmune disease. This is in accordance with other reports that showed a genetic risk determinant
mapped to the human leukocyte antigen (HLA) molecule in these patients. Further research is necessary to explore
whether IAA might be a separate entity with a role of antigen binding in the origin of the disease. (J Vasc Surg 2003;38:
492-7.)
Inflammatory aortic aneurysm (IAA) is a special variant
of abdominal aortic aneurysm (AAA) first described by
Walker et al.1 Hydronephrosis in AAA, described by James2
in 1935 and DeWeerd et al3 in 1955, was probably caused
by the same condition. Other investigators have stated that
one can observe, to varying degree, the same type of
inflammation in all atherosclerotic aneurysms.4,5 IAA is
characterized by a gray-white appearance observed during
operation. Thickened aneurysm wall, perianeurysmal fibro-
sis, and dense adhesions to adjacent abdominal organs such
as the duodenum and ureter are characteristic of IAA.1,6 In
particular, the anterior and lateral walls of the aneurysm are
thickened, and the inflammatory tissue includes abundant
infiltration of lymphocytes and plasma cells.5,7,8 There is a
similarity to idiopathic retroperitoneal fibrosis or periaortic
fibrosis.9 The histologic appearance of IAA is almost iden-
tical to giant cell arteritis.
The association between AAA, giant cell arteritis, and
Takayasu disease has been described.10 In contrast, Ehren-
feldt et al11 did not find any association between aortic
aneurysm or aortic dissection and occurrence of giant cell
arteritis or polymyalgia rheumatica. In review of our cohort
of AAA, it was striking that several patients with IAA had
autoimmune disease, eg, rheumatoid arthritis, systemic lu-
pus erythematosus (SLE), and giant cell arteritis. Further, it
has been suggested that certain genetic risk factors can be
identified in patients with IAA, indicating an autoimmune
mechanism.6,12
The purpose of our study was to investigate whether
there is a higher incidence of autoimmune disease in pa-
tients with IAA. Further we explored risk factors, need for
in-hospital resources, and early results after treatment in
patients with IAA compared with patients with noninflam-
matory AAA.
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MATERIAL AND METHODS
From 1983 to 1994, 520 patients were operated on
because of AAA. All patient records were reviewed, and the
cohort was reexamined in the outpatient clinic or by ques-
tionnaire to surviving subjects 5 to 16 years after the
operation. Thus 100% follow-up was obtained. In 31 pa-
tients (6%) the operating surgeon diagnosed IAA. The
macroscopic criteria for IAA used in our department in-
clude white glistening perianeurysmal fibrosis, thickened
aneurysm wall, and dense adhesions of adjacent abdominal
organs.13 In 21 cases the diagnosis was confirmed at histo-
logic examination with hematoxylin-eosin-saffran staining.
Characteristic findings at microscopy were loss of smooth
muscle cells and elastic tissue in the media, which in most
cases was extensively replaced with fibrous tissue. The
periaortic tissue exhibited granulation tissue with fibrosis
and a lymphoplasmocytic inflammatory infiltrate, often
with follicular aggregations of mature lymphoid cells.
Granulomas were not observed.7 Aneurysm wall thickening
was recorded in all patients either intraoperatively, on the
histologic specimen obtained during surgery, or on preop-
erative computed tomography scans.
Six patients (19.4%) with IAA were women; median
patient age was 70 years (Table I). Twelve IAA (39%) were
asymptomatic, 15 IAA (49%) were symptomatic without
rupture, and 4 IAA (13%) were ruptured.
The study design was case-control within a cohort. The
control group was matched for rupture, emergency or
elective hospital admission, and date of operation. Control
subjects were selected from a group of patients with non-
inflammatory AAA, and 2 control subjects were included
for every patient with IAA, for a control group with 62
patients. Control subjects included the last patient operated
on before and the first patient operated on after each
patient with IAA. For patients with ruptured IAA, the last
patient with ruptured non-IAA before and the first patient
after served as controls. Review of medical records and
follow-up were performed similarly in both groups. The
diagnosis of autoimmune disease was made before surgery
in all cases, and was verified by a rheumatologist from
clinical investigation, serologic tests, and biopsy findings,
when needed. We also compared the patients with IAA
with the total group of 489 patients operated on to treat
non-IAA during the study period. Because the control
group was matched for rupture, and type of admission was
related to occurrence of symptoms, we compared the inci-
dence of symptoms with the total group of 341 patients
with nonruptured AAA.
In-hospital resources were estimated from patient
records. Length of stay, stay in the intensive care unit or
intermediate care unit, operating time, anesthesia time
(total time in the operating room), and need for assisted
ventilation and blood transfusions were recorded. From
preoperative investigations, concomitant diseases such as
coronary heart disease (angina, previous myocardial infarc-
tion, percutaneous coronary intervention, or aortocoro-
nary bypass grafting), hypertension treated medically, renal
failure (creatinine concentration 140 mol/L), chronic
obstructive pulmonary disease, and diabetes were also
noted.
The investigation was approved by the local ethics
committee. Data were entered into the statistical database
Medlog, with which analysis also was performed. For sta-
tistical analysis the nonparametric Wilcoxon rank sum test
and 2 test, with appropriate corrections, were used. Ob-
served differences with P .05 were considered statistically
significant.
RESULTS
Of the 31 patients with IAA, autoimmune disease was
diagnosed in 6 before surgery. In contrast, no autoimmune
Table II. Prevalence of autoimmune disease in 31
patients with IAA and 62 control patients with
noninflammatory AAA
IAA Controls P
Autoimmune diseases 6 (19.3%) 0 .0017
Rheumatoid arthritis 3 —
Systemic lupus erythematosus 2 —
Giant cell arteritis 1 —
IAA, Inflammatory aortic aneurysm; AAA, abdominal aortic aneurysm.
Table I. Age, sex, and prevalence of comorbidity in 31 patients with IAA and 62 control patients with AAA
IAA Controls
SignificanceN % N %
Age (y, median) 69.9 70.6 NS
Gender
Male 25 81 48 77 NS
Female 6 19 14 23 NS
Comorbidity
Coronary heart disease 11 35 20 32 NS
Chronic obstructive pulmonary disease 2 6 9 15 NS
Diabetes 2 6 3 4.8 NS
Renal failure 7 23 8 13 NS
Hypertension 8 26 17 27 NS
IAA, Inflammatory aortic aneurysm; AAA, abdominal aortic aneurysm; NS, not statistically significant.
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disease was found in the control subjects (P .0017; Table
II). Two patients (1 seropositive, 1 seronegative) had rheu-
matoid arthritis,14 and 2 patients had SLE.15 These diag-
noses were in accordance with the criteria set forth by the
American College of Rheumatology. Both patients with
SLE also had antiphospholipid syndrome. One of these
patients had low titer of antinuclear antibody, low titer of
antideoxyribonucleoprotein, anti–Sjo¨gren’s syndrome A
antibody, high titer of antiribonucleoprotein, and high titer
of anti-Smith antibody, and medium titers of anti-ribonu-
cleoprotein and anticardiolipin antibodies. This 39-year-
old woman had an aneurysm with diameter of 65 mm. The
other patient with SLE and antiphospholipid syndrome had
an autoantibody profile consisting of positive antinuclear
antibodies, medium titer of positive anticardiolipin anti-
bodies, low titer of anti–Sjo¨gren’s syndrome A antibody,
high titer of anti–Sjo¨gren’s syndrome B antibody, low titer
of anti-Smith antibody. One patient had undifferentiated
seronegative polyarthritis, which was diagnosed as rheuma-
toid arthritis. One patient had giant cell arteritis, docu-
mented by characteristic inflammatory lesions in the tem-
poral artery. Microscopy of the biopsy specimen showed
pronounced expansion of the internal lamina elastica, ne-
crotic and hyalinized lamina media, infiltration of mononu-
clear leukocytes in all layers, and giant cells in the internal
lamina elastica. American College of Rheumatology criteria
for classification of giant cell arteritis were fulfilled.16 In the
IAA group, 1 patient with rheumatoid arthritis, 1 patient
with SLE, and 1 patient with giant cell arteritis used oral
corticosteroid therapy; no patients in the control group
used such treatment.
In 3 of 489 patients (0.6%) with noninflammatory AAA
autoimmune disease was diagnosed at operation. This inci-
dence is significantly lower than in the patients with IAA
(P .001). One patient had sarcoidosis, 1 patient had SLE,
and 1 patient had giant cell arteritis.
Patients with nonruptured IAA (n  27) more often
had abdominal pain, compared with patients with nonrup-
tured AAA (n  341)(51.9% vs 30.2%; P  .04). In turn,
this seemed to cause a slight tendency toward urgent ad-
mission to hospital in the IAA group (48% vs 34%), but this
difference did not reach statistical significance (P  .20).
There was no significant difference in reports of back pain
or tenderness at clinical examination in the two groups.
In the IAA group, median aortic wall thickness was
11.2 mm (range, 4.2-25 mm). There were no significant
difference in maximal aneurysm diameter in the two
groups, with median diameter of 60 and 65 mm, respec-
tively. In patients with IAA, the duodenum was involved in
19 patients (61%) and the left renal vein in 5 patients (16%),
and in 9 patients (29%) the inflammatory reaction extended
beyond the aortic bifurcation. Eight patients (26%) in the
IAA group had hydronephrosis from involvement of the
urether, which was bilateral in 2 patients. Erythrocyte sed-
imentation rate was significantly higher in patients with
IAA compared with control subjects (28 vs 16 mm; P 
.01). General symptoms such as malaise and weight loss
were more often observed in patients with IAA than in the
control group (Table III).
There were no differences between groups with regard
to incidence of preoperative coronary heart disease, hyper-
tension, diabetes, or chronic obstructive pulmonary dis-
ease. Thus, with the exception of local fibrotic changes,
there were no differences in preoperative risk factors in the
two groups. Median operating time was significantly longer
in the IAA group compared with the control group (203 vs
160 minutes; P .003; Table IV). There was also a higher
need for blood transfusion in the IAA group (median, 6 vs
3 units of saline adenine glucose mannitol blood; P 
.009). However, there was no statistically significant differ-
ence in median postoperative hospital stay or time in the
intensive care unit (108 vs 92 hours; P  .209). Neither
was the need for assisted ventilation different (median, 0
hours). Thirty-day mortality among patients with IAA was
25% in those with ruptured aneurysm and 7.4% in patients
Table III. Symptoms and signs in patients with IAA compared with control subjects with noninflammatory AAA
IAA (N  30) Controls (N  62)
Pn % n %
General symptoms 7 23 3 4.8 .02
Joint phenomena 2 6.7 0 0 NS
ESR (median) (mm/L)* 28.0 16.5 .001
Hematocrit (median)* 0.38 0.43 .011
Aneurysm size (median) (mm) 65 60 NS
Duodenal involvement 19 61 — —
Aortoduodenal fistula 1 3.0 — —
Distal involvement† 9 27 — —
Hydronephrosis 8 26 1 1.6 .0008
Right side 2 1
Left side 3 0
Bilateral 3 0
IAA, Inflammatory aortic aneurysm; AAA, abdominal aortic aneurysm; ESR, erythrocyte sedimentation rate; NS, not significant.
*Patients and control subjects with ruptured aneurysms excluded.
†Inflammation extending onto common iliac arteries.
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with nonruptured aneurysm, and there was no difference
compared with the control subjects.
DISCUSSION
Walker et al1 found no evidence of a systemic collagen
disorder in their patients with IAA. However, other authors
have proposed an autoimmune predisposition in such pa-
tients.6 Prevalence of aortitis has been decribed in 10% of
patients with ankylosing spondylitis,17 and aortitis has also
been found in a proportion of patients with rheumatoid
arthritis.9 Further, accelerated atherosclerosis, including
plaque formation in the carotid arteries, and higher inci-
dence of death due to cardiac disease have also been ob-
served in this group.18-20 Although AAA has been de-
scribed in patients with various autoimmune diseases,21 to
our knowledge this is the first report to show a higher
incidence of autoimmune disease in patients with IAA
compared with matched control subjects with noninflam-
matory AAA. Evidence of a genetic predisposition for de-
velopment of IAA exists. Thus a genetic risk determinant
mapped to the HLA-DR molecule, and in particular to the
HLA-DRB1 locus and the alleles B1*15 and B1*0404,
suggests a role for genetic risk factors in IAA.6,11 Of inter-
est, substitution of a glutamine for a negatively charged
aspartic acid at the entrance to pocket 4 significantly
changes the binding of the pocket and therefore changes
antigen selection. This suggests a critical role for antigen
binding in the origin of the disease, and its distinct location
on the HLA-DR molecule suggests disease specificity,
compared with giant cell arteritis. HLA typing was not
possible in our patients, but is done in prospective studies.
Various environmental factors, eg, viruses, may have a role
in the triggering mechanisms for development of inflam-
matory rheumatic disease, connective tissue diseases, and
primary vasculitis. Tests for microbial antigens such as
herpes simplex virus and cytomegalovirus22-24 have not
been performed. However, detection of these viruses in
serum and in biopsy specimens of arterial wall can be done
in forthcoming studies. Microscopy of biopsy specimens
may be important to reveal cellular composition and depos-
its that reflect both extent and different types of immuno-
logic activity in the vascular wall.24
Inasmuch as the question of increased incidence of
autoimmune disease in IAA first was discussed after the
study had been completed, there was no chance that the
surgeons were biased and looked for autoimmune disease
more diligently in patients with IAA. Furthermore, our
criteria for IAA were the same during the entire study. In a
case-control study, matching of control subjects is impor-
tant. We decided to match for rupture and urgency of
admission when we identified the control group. Selecting
control subjects from the group of patients operated on
directly before or after the index patients was done to
provide comparable data, which compensated for any pos-
sible temporal differences in treatment policy. Primarily, we
approached the data via a nested case-control design. A
limitation of that design is not that we selected two control
subjects per index case, but that the number of patients
with the index condition, IAA, was restricted. It is recom-
mended that the number of control subjects be increased,25
as in our study, but not beyond 4:1. We choose 2:1 as a
compromise, ie, the last eligible patient before and the first
patient after each index case. However, to test our hypoth-
esis further, we compared the occurrence of autoimmune
diseases in the IAA group with that in the entire noninflam-
matory AAA group. A strength of the study was complete
follow-up of patients throughout the entire period before
introduction of endovascular procedures to treat AAA at
our hospital.
Our hospital serves a well-defined geographic area.
Autoimmune disease would have been recorded if the
patient had received any treatment at a hospital in the
region, because all patient records were thoroughly re-
viewed and 100% follow-up was obtained. We therefore
find it unlikely that any autoimmune disease in the control
group was missed.
The technical challenges represented by the inflamma-
tory changes are reflected in the longer operating time and
greater need for blood transfusion. This may be an argu-
ment in favor of endovascular therapy for IAA.26-28 Endo-
vascular repair is feasible in these cases,29 but both regres-
sion and proliferation of the inflammatory changes30 have
been reported. Therefore this treatment method remains
controversial. Thirty-day mortality of 7.4% in the patients
Table IV. Hospital resources used after operation in 31 patients with IAA compared with 62 control subjects with
noninflammatory AAA
IAA Controls
PMedian Range Median Range
Operating time (min) 205 110-320 160 65-381 .003
Anesthesia time (min) 300 185-455 274 125-535 .04
Postoperative hospital stay (h) 216 48-720 216 0-4416 NS
Intensive care/intermediate
care unit stay (h)
108 36-542 92 5-4416 NS
Postoperative artificial
ventilation (h)
0 0-144 0 0-3648 NS
Blood transfusion (median
units SAG)
6 3 .009
IAA, Inflammatory aortic aneurysm; AAA, abdominal aortic aneurysm; SAG, saline adenine glucose mannitol blood; NS, not significant.
JOURNAL OF VASCULAR SURGERY
Volume 38, Number 3 Haug et al 495
with nonruptured IAA seems high, but includes two pa-
tients who underwent emergency surgery. One patient had
acute ischemia of the left lower limb after arteriography.
Closed compartment syndrome developed, and fasciotomy
was required. Severe multiorgan failure developed, includ-
ing renal failure, and the patient died on the tenth postop-
erative day. The other patient underwent emergency sur-
gery because of pain, but there was no rupture. The
immediate postoperative course was uneventful, but on the
fifth postoperative day a large myocardial infarction oc-
curred, which was verified at autopsy.
We investigated data for patients operated on from
1983 to 1994 because at that time all AAAs were treated
with open surgery with a standardized technique that was
the same for all operating surgeons. In February 1995
endovascular treatment was introduced in our hospital, and
this technique has since been used in about 40% of cases.
Thus patients who underwent open surgery since 1995
were selected.
Mitchinson31 claimed that IAA, perianeurysmal fibro-
sis, and idiopathic retroperitoneal fibrosis are all a manifes-
tation of the same process, and therefore proposed the
common name periaortitis. This was later supported by
Martina et al32 in a series in which idiopathic retroperito-
neal fibrosis seemed to be related to a high incidence of
aortic atherosclerosis. Stella et al33 also showed that degree
of postoperative regression not unexpectedly is related to
cell-fibrosis ratio, in which fibrosis preponderance is related
to poor response with regard to regression of periaortic
thickening after graft implantation. The results are not
uniform, however,34-38 and progression after open repair as
well as endovascular repair have been reported.31,35 Several
reports of IAA and perianeurysmal fibrosis include a com-
bination of both conditions,1,37 and IAA, idiopathic retro-
peritoneal fibrosis, and perianeurysmal fibrosis are often
clinically indistinguishable when complicated with ure-
theral involvement.
In conclusion, our study has demonstrated an associa-
tion between IAA and autoimmune disease. This is in
accordance with other reports that showed a genetic risk
determinant mapped to the HLA molecule in these pa-
tients. The findings seem to contradict the theory that IAA
is only an end stage of an inflammatory process present in all
aortic aneurysms, and supports the theory that IAA is a
separate entity. In this series there was longer operating
time and higher need for blood transfusion after surgery to
treat IAA, compared with operations to treat noninflamma-
tory AAA. However, use of other hospital resources and
early mortality were similar in both groups.
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CORRECTIONS
In: “Pixel distribution analysis of B-mode ultrasound scan images predicts histologic features of atheroscle-
rotic carotid plaques” (Lal BK, Hobson RW II, Pappas PJ, Kubicka R, Hameed M, Chakhtura EY, et al.
J Vasc Surg 2002; 35:1210-7).
The name Ellie Y. Chakhtura is spelled incorrectly. The correct spelling is Elie Y. Chakhtoura.
In: “Carotid artery stenting: analysis of data for 105 patients at high risk” (Hobson RW II, Lal BK,
Chaktoura E, Goldstein J, Haser PB, Kubicka R, et al. J Vasc Surg 2003;37:1234-9).
The name Ellie Y. Chaktoura is spelled incorrectly. The correct spelling is Elie Y. Chakhtoura.
In: “Endothelial cell seeding fails to attenuate intimal thickening in balloon-injured rabbit arteries”
(Conte MS, Choudry RP, Shirakowa M, Fallon JT, Birinyi LK. J Vasc Surg 1995;21:413-21).
The name Choudry is spelled incorrectly. The correct spelling is Choudury.
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